FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - September 16, 2026 61 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARROS-1 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Addressing Mental Health Needs of Adolescent and Young Adult Cancer Survivors March 11, 2021 Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer? October 3, 2023 An Oncology Hospital at Home Model of Acute Care Shows Promise May 21, 2021 What Are Drug Shortages and How Can They Impact Care for... June 23, 2023 Load more HOT NEWS FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer Saying YES: Inspiring a Diverse Generation of Cancer Scientists Professional Runner and Mom of Two Shares Photo Of Belly Cavity... Mouse Study Points to Strategy for Preserving Bone During Chemotherapy
